Robeco Institutional Asset Management B.V. Takes Position in Chemours Company (The) (CC)

Robeco Institutional Asset Management B.V. purchased a new stake in shares of Chemours Company (The) (NYSE:CC) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 16,643 shares of the specialty chemicals company’s stock, valued at approximately $842,000.

Several other hedge funds have also added to or reduced their stakes in CC. Teachers Advisors LLC raised its stake in shares of Chemours Company (The) by 3.3% during the first quarter. Teachers Advisors LLC now owns 319,341 shares of the specialty chemicals company’s stock valued at $12,295,000 after acquiring an additional 10,093 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Chemours Company (The) by 43.8% during the first quarter. Dimensional Fund Advisors LP now owns 706,929 shares of the specialty chemicals company’s stock valued at $27,217,000 after acquiring an additional 215,490 shares during the last quarter. KCG Holdings Inc. bought a new position in shares of Chemours Company (The) during the first quarter valued at $231,000. United Capital Financial Advisers LLC bought a new position in shares of Chemours Company (The) during the first quarter valued at $203,000. Finally, Bank of America Corp DE raised its stake in shares of Chemours Company (The) by 5.3% during the first quarter. Bank of America Corp DE now owns 631,439 shares of the specialty chemicals company’s stock valued at $24,310,000 after acquiring an additional 31,939 shares during the last quarter. 72.99% of the stock is owned by hedge funds and other institutional investors.

Chemours Company (The) (NYSE:CC) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business posted $0.27 EPS. The firm’s revenue was up 14.8% compared to the same quarter last year.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. UBS AG raised shares of Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their price target for the company from $36.00 to $50.00 in a research note on Monday, August 7th. J P Morgan Chase & Co raised their price target on shares of Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research note on Friday, August 4th. Argus reissued a “buy” rating and set a $55.00 target price (up previously from $50.00) on shares of Chemours Company (The) in a research note on Thursday, August 10th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $50.00 target price (up previously from $48.00) on shares of Chemours Company (The) in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $52.75.

In related news, insider E Bryan Snell sold 10,000 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.24, for a total transaction of $462,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP David C. Shelton sold 5,908 shares of the company’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of $56.01, for a total transaction of $330,907.08. Following the sale, the senior vice president now owns 47,356 shares of the company’s stock, valued at $2,652,409.56. The disclosure for this sale can be found here. Insiders have sold a total of 77,142 shares of company stock valued at $3,953,265 over the last quarter. 1.14% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/11/02/robeco-institutional-asset-management-b-v-takes-position-in-chemours-company-the-cc.html.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

What are top analysts saying about Chemours Company (The)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemours Company (The) and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit